Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

Franz Zehentmayr; Elvis Ruznic; Petra Feurstein; Brigitte Langer; Brane Grambozov; Marisa Klebermass; Alexandra Hochreiter; Ayurzana Purevdorj; Georg Gruber; Danijela Minasch; Barbara Böhmer-Breitfelder; Claudia Steffal; Karoline Kirchhammer; Heidi Stranzl; Falk Röder; Karin Dieckmann; ALLSTAR Group

doi:10.3390/cancers17091443

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

Franz Zehentmayr^* (First author), Elvis Ruznic (Co-author), Petra Feurstein (Co-author), Brigitte Langer (Co-author), Brane Grambozov (Co-author), Marisa Klebermass (Co-author), Alexandra Hochreiter (Co-author), Ayurzana Purevdorj (Co-author), Georg Gruber (Co-author), Danijela Minasch (Co-author), Barbara Böhmer-Breitfelder (Co-author), Claudia Steffal (Co-author), Karoline Kirchhammer (Co-author), Heidi Stranzl (Co-author), Falk Röder (Co-author), Karin Dieckmann (Last author), ALLSTAR Group

^*Corresponding author for this work

Montanuniversität Leoben

Research output: Contribution to journal › Original Article › peer-review

1 Citation (Web of Science)

Original language	English
Journal	Cancers
DOIs	https://doi.org/10.3390/cancers17091443
Publication status	Published - 25 Apr 2025

Access to Document

10.3390/cancers17091443

Cite this

Zehentmayr, F., Ruznic, E., Feurstein, P., Langer, B., Grambozov, B., Klebermass, M., Hochreiter, A., Purevdorj, A., Gruber, G., Minasch, D., Böhmer-Breitfelder, B., Steffal, C., Kirchhammer, K., Stranzl, H., Röder, F., Dieckmann, K., & ALLSTAR Group (2025). Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). Cancers. https://doi.org/10.3390/cancers17091443

@article{77b023e7dcc54e87abffc1d179b58394,

title = "Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)",

author = "Franz Zehentmayr and Elvis Ruznic and Petra Feurstein and Brigitte Langer and Brane Grambozov and Marisa Klebermass and Alexandra Hochreiter and Ayurzana Purevdorj and Georg Gruber and Danijela Minasch and Barbara B{\"o}hmer-Breitfelder and Claudia Steffal and Karoline Kirchhammer and Heidi Stranzl and Falk R{\"o}der and Karin Dieckmann and \{ALLSTAR Group\}",

note = "Zehentmayr, Ruznic, Grambozov, Hochreiter, R{\"o}der: Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria; Lehr-KH Ordensklinikum Linz",

year = "2025",

month = apr,

day = "25",

doi = "10.3390/cancers17091443",

language = "English",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

}

Zehentmayr, F , Ruznic, E, Feurstein, P, Langer, B, Grambozov, B, Klebermass, M, Hochreiter, A, Purevdorj, A, Gruber, G, Minasch, D, Böhmer-Breitfelder, B, Steffal, C, Kirchhammer, K, Stranzl, H, Röder, F, Dieckmann, K & ALLSTAR Group 2025, 'Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)', Cancers. https://doi.org/10.3390/cancers17091443

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). / Zehentmayr, Franz (First author); Ruznic, Elvis (Co-author); Feurstein, Petra (Co-author) et al.
In: Cancers, 25.04.2025.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

AU - Zehentmayr, Franz

AU - Ruznic, Elvis

AU - Feurstein, Petra

AU - Langer, Brigitte

AU - Grambozov, Brane

AU - Klebermass, Marisa

AU - Hochreiter, Alexandra

AU - Purevdorj, Ayurzana

AU - Gruber, Georg

AU - Minasch, Danijela

AU - Böhmer-Breitfelder, Barbara

AU - Steffal, Claudia

AU - Kirchhammer, Karoline

AU - Stranzl, Heidi

AU - Röder, Falk

AU - Dieckmann, Karin

AU - ALLSTAR Group

N1 - Zehentmayr, Ruznic, Grambozov, Hochreiter, Röder: Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria; Lehr-KH Ordensklinikum Linz

PY - 2025/4/25

Y1 - 2025/4/25

U2 - 10.3390/cancers17091443

DO - 10.3390/cancers17091443

M3 - Original Article

C2 - 40361370

SN - 2072-6694

JO - Cancers

JF - Cancers

ER -

Zehentmayr F , Ruznic E, Feurstein P, Langer B, Grambozov B, Klebermass M et al. Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). Cancers. 2025 Apr 25. doi: 10.3390/cancers17091443